scholarly journals Intracerebral Hemorrhage as the Initial Presentation of Chronic Myeloid Leukemia: A Case Report and Review of the Literature

2020 ◽  
Vol 11 ◽  
Author(s):  
Huafeng Wang ◽  
Fei Cao ◽  
Jianhu Li ◽  
Ke Sun ◽  
Jie Jin ◽  
...  
2018 ◽  
Vol 12 (1) ◽  
Author(s):  
Pongprueth Rujirachun ◽  
Apichaya Junyavoraluk ◽  
Weerapat Owattanapanich ◽  
Voraparee Suvannarerg ◽  
Sirinart Sirinvaravong

Onkologie ◽  
2012 ◽  
Vol 35 (11) ◽  
pp. 690-693 ◽  
Author(s):  
Kmira Zahra ◽  
Wafa Ben Fredj ◽  
Yosra Ben Youssef ◽  
Houneida Zaghouani ◽  
Imène Chebchoub ◽  
...  

2015 ◽  
Vol 4 (3) ◽  
pp. 252-254 ◽  
Author(s):  
Chakroun-Walha Olfa ◽  
Rejeb Imen ◽  
Kammoun Leila ◽  
Ksibi Hichem ◽  
Ayadi Adnane ◽  
...  

1999 ◽  
Vol 23 (9) ◽  
pp. 851-854 ◽  
Author(s):  
P Solves ◽  
P Bolufer ◽  
J.A López ◽  
E Barragán ◽  
L Bellod ◽  
...  

2018 ◽  
Vol 2018 ◽  
pp. 1-4
Author(s):  
Bader Alharbi ◽  
Samer Alamri ◽  
Ahmed Mahdi ◽  
Siham Marghalani

Dasatinib is an oral second-generation multitarget tyrosine-kinase inhibitor (TKI) that is efficacious in treating imatinib-resistant chronic myeloid leukemia (CML) or intolerant cases. Noncutaneous adverse effects with dasatinib are well known in the literature, most commonly cytopenias and fluid retention, while pigmentary abnormalities have rarely been reported. We report the case of a 12-year-old male known case of CML, who presented to dermatology clinic approximately 2 years after initiating dasatinib treatment, with new-onset hypopigmentation of his upper limb, upper chest, and both knees of six months’ duration.


2009 ◽  
Vol 33 (8) ◽  
pp. 1079-1081 ◽  
Author(s):  
Salvatore Guastafierro ◽  
Umberto Falcone ◽  
Maria Celentano ◽  
Milena Coppola ◽  
Maria Giovanna Ferrara ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document